A longitudinal analysis of brain volume changes in myelin oligodendrocyte glycoprotein antibody‐associated disease

Abstract

AbstractBackground and PurposeMyelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is a relapsing demyelinating condition. There are several cross‐sectional studies showing evidence of brain atrophy in people with MOGAD (pwMOGAD), but longitudinal brain volumetric assessment is still an unmet need. Current recommendations do not include monitoring with MRI and assume distinct attacks. Evidence of ongoing axon loss will have diagnostic and therapeutic implications. In this study, we assessed brain volume changes in pwMOGAD over a mean follow‐up period of 2 years and compared this to changes in people with multiple sclerosis (pwMS).MethodsThis is a retrospective single‐center study over a 7‐year period from 2014 to 2021. MRI brain scans at the time of diagnosis and follow‐up in remission were collected from 14 Caucasian pwMOGAD, confirmed by serum myelin oligodendrocyte glycoprotein immunoglobulin G antibody presence, detected by live cell‐based assays. Total brain volume (TBV), white matter (WM), gray matter (GM), and demyelinating lesion volumes were assessed automatically using the Statistical Parametric Mapping and FMRIB automated segmentation tools. MRI brain scans at diagnosis and follow‐up on remission were collected from 32‐matched pwMS for comparison. Statistical analysis was done using analysis of variance.ResultsThere is evidence of TBV loss, affecting particularly GM, over an approximately 2‐year follow‐up period in pwMOGAD (p < .05), comparable to pwMS. WM and lesion volume change over the same period were not statistically significant (p > .1).ConclusionWe found evidence of loss of GM and TBV over time  in pwMOGAD, similar to pwMS, although the WM and lesion volumes were unchanged.